Genmab A/S (NASDAQ:GMAB) Expected to Post Q4 2023 Earnings of $0.32 Per Share

Genmab A/S (NASDAQ:GMABFree Report) – Equities research analysts at HC Wainwright increased their Q4 2023 earnings estimates for shares of Genmab A/S in a report released on Monday, January 29th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.32 per share for the quarter, up from their prior estimate of $0.25. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.19 per share. HC Wainwright also issued estimates for Genmab A/S’s Q1 2024 earnings at $0.15 EPS, Q2 2024 earnings at $0.30 EPS and FY2024 earnings at $1.08 EPS.

GMAB has been the subject of several other reports. BTIG Research upped their price target on Genmab A/S from $44.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday, October 13th. UBS Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, December 6th. Deutsche Bank Aktiengesellschaft upgraded Genmab A/S from a “hold” rating to a “buy” rating in a research report on Friday, November 10th. BNP Paribas initiated coverage on Genmab A/S in a research report on Wednesday, October 18th. They set an “underperform” rating for the company. Finally, Nordea Equity Research downgraded Genmab A/S from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $46.50.

Read Our Latest Stock Report on Genmab A/S

Genmab A/S Trading Down 1.8 %

NASDAQ:GMAB opened at $27.61 on Thursday. The company has a market cap of $18.24 billion, a PE ratio of 29.37, a price-to-earnings-growth ratio of 1.85 and a beta of 1.00. The company has a 50 day simple moving average of $30.83 and a two-hundred day simple moving average of $33.75. Genmab A/S has a 12 month low of $27.31 and a 12 month high of $42.99.

Genmab A/S (NASDAQ:GMABGet Free Report) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.13. The company had revenue of $692.80 million for the quarter, compared to analysts’ expectations of $657.79 million. Genmab A/S had a net margin of 25.54% and a return on equity of 15.03%.

Institutional Trading of Genmab A/S

A number of institutional investors have recently bought and sold shares of GMAB. First Manhattan Co. bought a new stake in Genmab A/S in the fourth quarter worth $26,000. Headlands Technologies LLC purchased a new stake in Genmab A/S in the third quarter worth $27,000. Pinnacle Bancorp Inc. increased its stake in Genmab A/S by 315.8% in the fourth quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after purchasing an additional 638 shares during the period. NBC Securities Inc. purchased a new stake in Genmab A/S in the third quarter worth $37,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Genmab A/S by 86.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock worth $38,000 after purchasing an additional 498 shares during the period. 6.29% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Featured Stories

Earnings History and Estimates for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.